

---

Subject: Fevipiprant (QAW039) | Oral PGD2 Antagonist  
Posted by [Nomadd](#) on Mon, 13 Feb 2017 00:48:59 GMT  
[View Forum Message](#) <> [Reply to Message](#)

---

Erst Setipiprant, dann TM30089 und jetzt auch noch Fevipiprant. Im Hairlosstalk organisieren sie die ersten Groupbuys...

Zitat:Studies

Science behind Fevipiprant  
Fevi vs Seti  
Binding Power and Affinity for the CRTH2 Receptor  
How PGD2 is responsible for hairloss  
Diagram

Media

Guardian - Asthma drug 'gamechanger' could revolutionise treatment  
PharmaTimes - Novartis' fevipiprant hailed a "game-changer" in asthma treatment

Side Effects & Safety

Similar to Seti which is mild and rare  
Practically no chance of sexual sides because it doesn't mess with hormones or PGD2 Production  
See here  
Fevipiprant is in phase 3 trials all over the world. You do not usually reach Phase 3 unless safety is sufficiently established and that many trials indicates it would be safe. And they already looking at Asthma mild all the way to severe, atopic dermatitis and rhinitis.

Quelle:

<https://www.hairlosstalk.com/interact/threads/qaw039-fevipiprant-interest-thread-oral-once-a-day-pgd2-antagonist.103292/>

---